EDAP TMS (FOCL) Registration filing summary

Company overview and business model

• Develops, manufactures, promotes, and distributes minimally invasive ultrasound technologies for diagnosis and treatment, including the Focal One® Robotic HIFU system, with global reach in Europe, the U.S., Latin America, and Asia.

• Maintains legacy urology product lines and distributes third-party products, supporting a broad installed base and recurring service revenue.

• Registered in France, with principal offices in Vaulx-en-Velin, France, and U.S. operations in Austin, Texas.

• Operates as a "smaller reporting company" under SEC rules, allowing for scaled disclosure requirements.

Financial performance and metrics

• As of March 25, 2026, had 37,751,519 issued ordinary shares, fully paid, with a nominal value of €0.13 per share.

• No preferred shares outstanding as of the filing date.

Use of proceeds and capital allocation

• Net proceeds from securities sales are intended for operating costs, capital expenditures, and general corporate purposes, including working capital.

• May use a portion of proceeds for acquisitions or investments in complementary businesses or technologies, though no current commitments exist.

• Proceeds from warrant exercises by the selling securityholder will be used for general corporate purposes, including working capital.